Table 4.
Primary and Secondary Outcomes of the Included Studies in the 2-arm Meta-Analysis.
| Study, year | Mortality | Need for endotracheal intubation | Hospital length of stay (Days) | |||
|---|---|---|---|---|---|---|
| IPVD (%) | Standard therapy (%) | IPVD (%) | Standard therapy (%) | IPVD (SD) | Standard therapy (SD) | |
| Chandel 2021 | 12 (18.2) | 36 (17.5) | 29 (43.9) | 79 (38.3) | 20.7 (15.2) | 15.1 (8.2) |
| Kataria 2022 | 13 (43.3) | 14 (46.7) | 21 (70) | 27 (90) | 38.1 (57.8) | 43 (66.4) |
| Matthews 2022 | 31 (52.5) | 199 (79.9) | NR | NR | NR | NR |
Abbreviations: IPVD, Inhaled Pulmonary Vasodilators; NR, Not Reported; SD, Standard Deviation.